Advertisement
Australia markets close in 5 hours 23 minutes
  • ALL ORDS

    7,848.10
    -89.40 (-1.13%)
     
  • ASX 200

    7,588.00
    -95.00 (-1.24%)
     
  • AUD/USD

    0.6526
    +0.0003 (+0.04%)
     
  • OIL

    83.89
    +0.32 (+0.38%)
     
  • GOLD

    2,341.20
    -1.30 (-0.06%)
     
  • Bitcoin AUD

    98,421.98
    -612.90 (-0.62%)
     
  • CMC Crypto 200

    1,387.98
    +5.41 (+0.39%)
     
  • AUD/EUR

    0.6081
    +0.0008 (+0.13%)
     
  • AUD/NZD

    1.0940
    -0.0017 (-0.16%)
     
  • NZX 50

    11,890.15
    -56.28 (-0.47%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    17,917.28
    -171.42 (-0.95%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • NIKKEI 225

    37,611.15
    -17.33 (-0.05%)
     

Gilead Sciences Stock: Bear vs. Bull

Gilead Sciences Stock: Bear vs. Bull

You may know of Gilead Sciences (NASDAQ: GILD) because of its blockbuster coronavirus treatment Veklury. In fact, the S&P 500 has outperformed Gilead over the past five years. Gilead has struggled to consistently deliver annual revenue growth ever since its hepatitis C portfolio's revenue reached a peak back in 2015.